ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1901

Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study
Abstract Number: 1902

Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Abstract Number: 1903

Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
Abstract Number: 1904

Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Abstract Number: 1905

Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
Abstract Number: 1906

Bayesian Algorithm to Identify Osteoarthritis in Administrative Health Data Without Requiring Chart Review
Abstract Number: 1907

Community-Engaged Curriculum Development Using Racial Justice and Biomedical Lenses to Address COVID-19 Vaccine Hesitancy in Black Individuals with Rheumatologic Conditions
Abstract Number: 1908

Male Sex, Medical Comorbidity and Post-procedure Complications Are Associated with Higher In-hospital Mortality After Primary Total Knee Arthroplasty for Osteoarthritis
Abstract Number: 1909

Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study
Abstract Number: 1910

Appointment Adherence: Impact of Health Portal Access, Letters, Phone Calls and Text Message Reminders in Underserved Population
Abstract Number: 1911

Improving Healthcare Access in Underserved Brooklyn Communities: A Comprehensive Multispecialty Patient Navigator Program
Abstract Number: 1912

Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Abstract Number: 1913

Health Literacy and Disease, Clinical, Functional and Management Outcomes in Inflammatory Arthritis: A Systematic Literature Review
Abstract Number: 1914

Racial and Ethnic Differences in the Prevalence of Disease Features in Systemic Sclerosis
Abstract Number: 1915

Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].